NY-NFL/OVERTIER
7.10.2019 16:58:06 CEST | Business Wire | Press release
The National Football League (NFL) and OverTier, a Bruin Sports Capital (Bruin) company, today announced an expansion of their partnership for OverTier to operate NFL Game Pass, the league’s premium subscription OTT service. Since 2017, OverTier held the rights to operate NFL Game Pass in Europe. The new agreement now brings the service to a combined 181 countries and territories worldwide including Australia, Brazil, Hong Kong, India, Israel, Japan, Mexico, and South Korea.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191007005597/en/
NFL Game Pass offers all live NFL Games, NFL Red Zone, NFL Network and a deep catalog of original programming, documentaries, series and specials from the award-winning NFL Films. It is available across 11 platforms through connected TV, games consoles, web and mobile.
“We are excited to expand our partnership with OverTier to bring the NFL directly to fans around the world on their favorite viewing platforms with NFL Game Pass,” said Chris Halpin, NFL Chief Strategy & Growth Officer. “OverTier has a proven track record of innovation in Europe, and we look forward to unlocking significant potential across other markets.”
“We are delighted with the progress we’ve made with our NFL partners. Together we have built a detailed understanding of how to cultivate and super serve fans throughout Europe and have turned that into meaningful business gain with great long-term potential,” said Sam Jones, OverTier CEO. “We look forward to applying our unique model to these expanded global markets and with the league develop more fans and opportunities worldwide.”
Over the past two seasons, a suite of user-led product innovations delivered a more personalized viewing experience to more fans across more platforms and services in Europe than ever. There has been a meaningful growth in subscriptions to NFL Game Pass in Europe, total NFL GPE regular-season viewership was up 46% year-on-year (’17-’18), with average minutes per viewer increasing by 20% to 62 hours. Live Super Bowl viewership was up 33% year-on-year and playoff viewership up 30%. Mobile viewership increased by 26% year-on-year, while the total number of devices subscribers used to watch GPE increased by 33% (a GPE subscription allows up to five concurrent streams). Eight hundred million hours of content was streamed, representing over 91,000 years of content. The Android app was the highest rated of all sports subscription OTT services globally.
OverTier was created by Bruin to build and operate next-generation, sports, and entertainment direct-to-consumer streaming services. Bruin company, Deltatre, the global leader in sports media technology, provides the streaming platform technology. All marketing for OverTier on behalf of NFL Game Pass is led by Two Circles, a data-driven sports agency, with the support of Wavemaker, a full-service global media agency, both part of WPP’s GroupM.
Among the innovations to be rolled out in 2019 are:
- Watch Around The World: NFL Game Pass subscribers will be able to use their subscription in any of the 181 territories it is active
- Watch with RedZone: Thanks to new split-screen functionality, Season Pro subscribers will be able to watch NFL RedZone alongside one live game (outside of Europe).
- Smart TV and PS4 apps: NFL Game Pass is accessible on more devices, including Samsung and LG Smart TVs
- Film Sessions - Season 2: Across the 2019 season, 17 new installments of the hit series NFL Game Pass: Film Sessions will be available exclusively to NFL Game Pass International subscribers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005597/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom